APRIL Serum Biomarker Detection for Autoimmune Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for identifying expression patterns of TNFR ligands associated with autoimmune diseases like rheumatoid arthritis (RA) for early diagnosis and predicting disease severity and treatment response, as existing methods lack specificity and timing information.
Innovation Solution
A method for screening APRIL levels in serum to diagnose autoimmune diseases, particularly RA, by measuring APRIL protein expression and comparing it to healthy controls, which helps in predicting disease severity and selecting effective treatment plans involving APRIL and/or BLyS antagonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If APRIL level measurement method is used for early diagnosis of autoimmune diseases, then diagnostic timing and specificity are improved, but the complexity of the diagnostic system increases
Solution Approach 1:
The patent extracts and measures specifically APRIL protein levels from complex biological samples (serum, plasma, or other body fluids) using ELISA or other immunoassay methods. By focusing on this single biomarker rather than attempting to analyze multiple parameters simultaneously, the method achieves early diagnostic capability while maintaining relatively simple procedural complexity.
Solution Approach 2:
The patent uses antibodies as intermediary molecules to detect APRIL levels. These antibodies serve as mediators that specifically bind to APRIL, enabling indirect measurement of the biomarker. This intermediary approach allows for highly specific detection without requiring direct interaction between the diagnostic system and the target protein, thereby improving measurement precision while managing system complexity.
2Adaptability or versatility
If APRIL level measurement is used to predict disease severity and treatment response, then treatment personalization is improved, but the cost and complexity of treatment selection increases
Solution Approach 1:
The patent performs APRIL level measurement before treatment initiation (pre-treatment baseline assessment) to predict disease severity and potential treatment response. By conducting this assessment in advance, the system enables personalized treatment selection from the outset rather than requiring complex adjustments during treatment, thereby improving adaptability while managing selection complexity.
Solution Approach 2:
The patent uses APRIL protein concentration levels as a quantitative parameter to stratify patients into different risk categories or treatment response groups. By changing the treatment selection basis from multiple clinical parameters to a single quantifiable biomarker (APRIL level), the system achieves treatment personalization while simplifying the decision-making process.
Data Source
AI summary
The present invention provides a method of measuring the levels of APRIL in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as RA, predicting the future severity of the disease, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with APRIL antagonists, either singly or in combination with other immune suppressive drugs.